Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma

Published:2020-02-22 Issue:7 Volume:61 Page:1732-1735
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kort Jeries¹^ORCID,Chidiac Amanda¹,El Sayed Rola¹,Massoud Radwan¹,Nehme Rita¹,Bazarbachi Ali¹,El-Cheikh Jean¹^ORCID

Affiliation:

1. Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1728755

Reference11 articles.

1. The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma

2. State-of-the-Art Therapeutics: Hodgkin's Lymphoma

3. Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma

4. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of transplantation in Hodgkin lymphoma;Frontiers in Oncology;2023-01-26

2. Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy;Cancers;2021-12-05

3. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies;Blood Cancer Journal;2021-07

4. Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study;Hematological Oncology;2021-06-25

5. Fenntartó kezelési módok felnőttkori rosszindulatú hematológiai betegségekben;Orvosi Hetilap;2020-09